Investors focused on the Medical space have likely heard of Array BioPharma (ARRY Quick QuoteARRY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Array BioPharma is one of 839 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ARRY is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for ARRY's full-year earnings has moved 9.69% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, ARRY has moved about 25.40% on a year-to-date basis. In comparison, Medical companies have returned an average of 2.64%. This means that Array BioPharma is outperforming the sector as a whole this year.

Looking more specifically, ARRY belongs to the Medical - Biomedical and Genetics industry, which includes 345 individual stocks and currently sits at #58 in the Zacks Industry Rank. This group has gained an average of 8.89% so far this year, so ARRY is performing better in this area.

Investors with an interest in Medical stocks should continue to track ARRY. The stock will be looking to continue its solid performance.